Generic medication company Upsher-Smith Laboratories LLC reported on Tuesday the receipt of approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for Bumetanide Tablets, USP in 0.5 mg, 1 mg and 2 mg for treating fluid retention in the body.
According to the company, Bumetanide Tablets are a generic version of the brand product, Bumex (bumetanide) Tablets.
The company will begin shipping Bumetanide Tablets to wholesalers in early February 2018.
Bumetanide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. Therefore, careful medical supervision is required, and dose and dosage schedule have to be adjusted to the individual patient's needs, added the company.
For the 12 months ending November 2017, the bumetanide tablet market had US sales of approximately USD84.5m, according to IMS Health.
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US